Idelalisib is effective in patients with high-risk follicular lymphoma and early relapse after initial chemoimmunotherapy

Ajay K. Gopal, Brad S. Kahl, Christopher R. Flowers, Peter Martin, Stephen Maxted Ansell, Esteban Abella-Dominicis, Brian Koh, Wei Ye, Paul M. Barr, Gilles A. Salles, Jonathan W. Friedberg

Research output: Contribution to journalReview article

37 Citations (Scopus)
Original languageEnglish (US)
Pages (from-to)3037-3039
Number of pages3
JournalBlood
Volume129
Issue number22
DOIs
StatePublished - Jun 1 2017

ASJC Scopus subject areas

  • Immunology
  • Biochemistry
  • Hematology
  • Cell Biology

Cite this

Gopal, A. K., Kahl, B. S., Flowers, C. R., Martin, P., Ansell, S. M., Abella-Dominicis, E., ... Friedberg, J. W. (2017). Idelalisib is effective in patients with high-risk follicular lymphoma and early relapse after initial chemoimmunotherapy. Blood, 129(22), 3037-3039. https://doi.org/10.1182/blood-2016-12-757740

Idelalisib is effective in patients with high-risk follicular lymphoma and early relapse after initial chemoimmunotherapy. / Gopal, Ajay K.; Kahl, Brad S.; Flowers, Christopher R.; Martin, Peter; Ansell, Stephen Maxted; Abella-Dominicis, Esteban; Koh, Brian; Ye, Wei; Barr, Paul M.; Salles, Gilles A.; Friedberg, Jonathan W.

In: Blood, Vol. 129, No. 22, 01.06.2017, p. 3037-3039.

Research output: Contribution to journalReview article

Gopal, AK, Kahl, BS, Flowers, CR, Martin, P, Ansell, SM, Abella-Dominicis, E, Koh, B, Ye, W, Barr, PM, Salles, GA & Friedberg, JW 2017, 'Idelalisib is effective in patients with high-risk follicular lymphoma and early relapse after initial chemoimmunotherapy', Blood, vol. 129, no. 22, pp. 3037-3039. https://doi.org/10.1182/blood-2016-12-757740
Gopal, Ajay K. ; Kahl, Brad S. ; Flowers, Christopher R. ; Martin, Peter ; Ansell, Stephen Maxted ; Abella-Dominicis, Esteban ; Koh, Brian ; Ye, Wei ; Barr, Paul M. ; Salles, Gilles A. ; Friedberg, Jonathan W. / Idelalisib is effective in patients with high-risk follicular lymphoma and early relapse after initial chemoimmunotherapy. In: Blood. 2017 ; Vol. 129, No. 22. pp. 3037-3039.
@article{f2a8e84a61ee4243a749c593cadbe9c3,
title = "Idelalisib is effective in patients with high-risk follicular lymphoma and early relapse after initial chemoimmunotherapy",
author = "Gopal, {Ajay K.} and Kahl, {Brad S.} and Flowers, {Christopher R.} and Peter Martin and Ansell, {Stephen Maxted} and Esteban Abella-Dominicis and Brian Koh and Wei Ye and Barr, {Paul M.} and Salles, {Gilles A.} and Friedberg, {Jonathan W.}",
year = "2017",
month = "6",
day = "1",
doi = "10.1182/blood-2016-12-757740",
language = "English (US)",
volume = "129",
pages = "3037--3039",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "22",

}

TY - JOUR

T1 - Idelalisib is effective in patients with high-risk follicular lymphoma and early relapse after initial chemoimmunotherapy

AU - Gopal, Ajay K.

AU - Kahl, Brad S.

AU - Flowers, Christopher R.

AU - Martin, Peter

AU - Ansell, Stephen Maxted

AU - Abella-Dominicis, Esteban

AU - Koh, Brian

AU - Ye, Wei

AU - Barr, Paul M.

AU - Salles, Gilles A.

AU - Friedberg, Jonathan W.

PY - 2017/6/1

Y1 - 2017/6/1

UR - http://www.scopus.com/inward/record.url?scp=85020257653&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85020257653&partnerID=8YFLogxK

U2 - 10.1182/blood-2016-12-757740

DO - 10.1182/blood-2016-12-757740

M3 - Review article

C2 - 28325864

AN - SCOPUS:85020257653

VL - 129

SP - 3037

EP - 3039

JO - Blood

JF - Blood

SN - 0006-4971

IS - 22

ER -